Fig. 4: Potent in vivo effects of synthetic ecteinascidins.
a,b Indicated CDX models (n = 10 at the beginning of the experiment) from LOX-IMVI a or WM-266-4 b melanoma cells were treated with placebo, ecubectedin or PM54 at 1.2 mg/kg once a week for 3 consecutive weeks (on days 0, 7 and 14) and tumor volumes were measured. Results are shown as mean values ± SD for “n” mice. The red bar indicates the dose period. The latency phase is indicated by an arrow. Logrank (Mantel–Cox) test was used to determine the p-values. Source data are provided as a Source Data file. c, d Indicated CDX models (n = 10 at the beginning of the experiment) from LOX-IMVI c or WM-266-4 d melanoma cells were treated weekly with Placebo, ecubectedin or PM54 at 1.2 mg/kg and survival was assessed. Results are shown as mean values ± SD for “n” mice. The red bar indicates the dose period. The latency phase is indicated by an arrow. Logrank (Mantel–Cox) test was used to determine the p-values. Source data are provided as a Source Data file. e, f Indicated CDX models (n = 8 at the beginning of the experiment) from 501mel e or 501melVemuR f melanoma cells were treated once with Placebo, ecubectedin or PM54 at 1.2 mg/kg and tumor volumes were measured. Results are shown as mean values ± SD for “n” mice. Logrank (Mantel–Cox) test was used to determine the p-values. Source data are provided as a Source Data file. g, h Indicated CDX models (n = 8 at the beginning of the experiment) from 501mel g or 501melVemuR h melanoma cells were treated once with Placebo, ecubectedin or PM54 at 1.2 mg/kg and survival was assessed. Results are shown as mean values ± SD for “n” mice. Logrank (Mantel–Cox) test was used to determine the p-values. Source data are provided as a Source Data file.
